Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/00, 30/9/01, 11/3/02, 1/1/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

CAPITOL HEALTH LIMITED		
ABN		
84 117 391 812		
Wa (the antity) give ACV the fel	1i. Como di co	

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 \*Class of \*securities issued or to be issued

**Unlisted Options** 

Number of \*securities issued or to be issued (if known) or maximum number which may be issued

1,000,000

3 Principal terms of the \*securities (eg, if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

Unlisted Options (**Options**) exercisable at \$0.2372 (23.72 cents) per Option and expire on 11 September 2022. The Options will vest in two tranches subject to satisfaction of vesting conditions:

- The first tranche of 500,000 Options vests on or around 11 March 2021; and
- The second tranche of 500,000 Options vests on or around 11 March 2022.

04/03/2013 Appendix 3B Page 1

<sup>+</sup> See chapter 19 for defined terms.

4 No. Do the \*securities rank equally in all respects from the +issue date with an existing \*class of quoted \*securities? The Options will not be quoted. Shares to be issued upon conversion of the Options will rank equally If the additional securities do not rank with all other fully paid ordinary shares on issue. equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 5 Nil Issue price or consideration 6 Issue of Options to eligible participant pursuant to Purpose of the issue the Company's Employee Incentive Plan as (If issued as consideration for the acquisition of assets, clearly identify approved by shareholders on 19 November 2018. those assets) 6a Is the entity an<sup>+</sup>eligible entity that has No obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder resolution N/A under rule 7.1A was passed 6c Number of \*securities issued without N/A security holder approval under rule 7.1 6d Number of +securities issued with N/A security holder approval under rule 7.1A 6e Number of +securities issued with N/A security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) 6f Number of securities issued under an 1,000,000 Options exception in rule 7.2

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A	
		<u> </u>	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue	Rule 7.1:	117,835,339
	capacity under rule 7.1 and rule 7.1A  – complete Annexure 1 and release to ASX Market Announcements	Rule 7.1A:	N/A.
7	<sup>+</sup> Issue dates	11 March 2019	
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.		
	Cross reference: item 33 of Appendix 3B.		
		Number	<sup>+</sup> Class
8	Number and *class of all *securities quoted on ASX ( <i>including</i> the securities in clause 2 if applicable)	785,568,931	Fully Paid Ordinary Shares
		Number	+Class
9	Number and <sup>+</sup> class of all <sup>+</sup> securities not quoted on ASX ( <i>including</i> the	29,900,000	Unlisted Options
	securities in clause 2 if applicable)	3,439,827	Unlisted Performance Rights
10	Dividend policy (in the case of atrust, distribution policy) on the increased capital (interests)	N/A	

04/03/2013 Appendix 3B Page 3

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2 - Pro rata issue

**Questions 11 to 33 - Not Applicable** 

#### Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

Type of securities
 (tick one)
 (a) Securities described in Part 1
 (b) All other securities
 Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

**Questions 35 to 37 - Not Applicable** 

Entities that have ticked box 34(b)

**Questions 38 to 42 - Not Applicable** 

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- 1 <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Date: 14 March 2019 (Company Secretary) Sign here:

Print name: Melanie Leydin

04/03/2013 Appendix 3B Page 5

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B - Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for +eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital				
Step 1: Calculate "A", the base figure from which the placement capacity is calculated				
Insert number of fully paid ordinary securities on issue 12 months before †issue date or date of agreement to issue	802,456,607			
Add the following:     Number of fully paid ordinary securities issued in that 12 month period under	1,000,000 – 22 March 2018 2,507,592 – 3 April 2018			
<ul> <li>an exception in rule 7.2</li> <li>Number of fully paid ordinary securities</li> </ul>	1,837,442 – 25 October 2018			
issued in that 12 month period with shareholder approval				
Number of partly paid ordinary securities that became fully paid in that 12 month period				
Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items				
Subtract the number of fully paid  †ordinary securities cancelled during that  12 month period	22,232,710			
"A"	785,568,931			

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"				
"B"	0.15			
	[Note: this value cannot be changed]			
<b>Multiply</b> "A" by 0.15	117,835,339			
Step 3: Calculate "C", the amount of placement capacity under rul 7.1 that has already been used				
<i>Insert</i> number of *equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	-			
• Under an exception in rule 7.2				
Under rule 7.1A				
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>				
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>				
"C"	-			
Step 4: Subtract "C" from ["A" x ' placement capacity under rule 7.1	-			
"A" x 0.15	117,835,339			
Note: number must be same as shown in Step 2				
Subtract "C"	-			
Note: number must be same as shown in Step 3				
<i>Total</i> ["A" x 0.15] – "C"	117,835,339			
	[Note: this is the remaining placement capacity under rule 7.1]			

04/03/2013 Appendix 3B Page 7

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement	capacity for eligible entities			
Step 1: Calculate "A", the base figure from which the placement capacity is calculated				
"A"	N/A			
Note: number must be same as shown in Step 1 of Part 1				
Step 2: Calculate 10% of "A"				
"D"	Note: this value cannot be changed			
<b>Multiply</b> "A" by 0.10				
Step 3: Calculate "E", the amount of բ 7.1A that has already been used	placement capacity under rule			
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period under rule 7.1A				
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>				
"E"				
Step 4: Subtract "E" from ["A" x "D"] placement capacity under rule 7.1A	to calculate remaining			
"A" x 0.10				
Note: number must be same as shown in Step 2				
Subtract "E"				
Note: number must be same as shown in Step 3				
<i>Total</i> ["A" x 0.10] – "E"	Note: this is the remaining placement capacity under rule 7.1A			

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B Page 8 04/03/2013